1. Executive Summary
1.1 Antithrombotic/Anticoagulant Drug: World Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. Blood Clotting: Mechanism, Disorders and Treatments
2.1 Thrombosis
2.1.1 Venous Thrombosis
2.1.2 Arterial Thrombosis
2.2 Complications of Thrombosis
2.2.1 Pulmonary Embolism
2.2.2 Stroke
2.2.3 Myocardial Infarction
2.2.4 Acute Coronary Syndrome
2.3 Antithrombotic Treatments
2.3.1 Platelet Aggregation Inhibitors
2.3.1.1 Glycoprotein Inhibitors
2.3.1.2 Aspirin
2.3.1.3 Thienopyridines
2.3.2 Heparins
2.3.3 Fibrinolytics
2.3.3.1 Streptokinase and Urokinase
2.3.3.2 Tissue Plasminogen Activator (tPA)
2.3.3.3 Other Thrombolytic Agents
2.3.4 Vitamin K Antagonists
2.3.5 Direct Thrombin Inhibitors
2.3.6 Direct Factor Xa Inhibitors
3. Antithrombotic Drugs: World Market 2012-2022
3.1 The Antithrombotic/Anticoagulant Drug Market in 2010
3.2 The Antithrombotic/Anticoagulant Drug Market Forecast 2012-2022
3.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes
3.3.1 The Leading Therapeutic Classes in 2010
3.3.2 Leading Therapeutic Class Forecast 2012-2022
3.4 Platelet Aggregation Inhibitors
3.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2010
3.4.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2022
3.5 Heparins
3.5.1 The Heparins Market in 2010
3.5.2 Heparins: Market Forecast 2012-2022
3.6 Fibrinolytics
3.6.1 The Fibrinolytics Market in 2010
3.6.2 Fibrinolytics: Market Forecast 2012-2022
3.7 Vitamin K Antagonists
3.7.1 Vitamin K Antagonists Market in 2010
3.7.2 Vitamin K Antagonists Market Forecast 2012-2022
3.8 Direct Thrombin Inhibitors
3.8.1 Direct Thrombin Inhibitors Market in 2010
3.8.2 Direct Thrombin Inhibitors: Market Forecast 2012-2022
3.9 Direct Factor Xa Inhibitors
3.9.1 Direct Factor Xa Inhibitors Market in 2010
3.9.2 Direct Factor Xa Inhibitors: Market Forecast 2012-2022
3.10 Chapter Summary
4. Leading National Markets for Antithrombotic/Anticoagulant Drugs, 2012-2022
4.1 Leading National Markets in 2010
4.2 Leading National Markets: Forecasts to 2022
4.3 The US Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.4 The Japanese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.5 Leading European Antithrombotic/Anticoagulant Drug Markets, 2012-2022
4.6 The Chinese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.7 The Indian Antithrombotic/Anticoagulant Drug Market, 2012-2022
5. Leading Antithrombotic/Anticoagulant Drugs, 2012-2022
5.1 The Leading Drugs of 2010
5.2 Plavix - Commercial Prospects
5.2.1 Plavix: The Leading Anticoagulant of 2010
5.2.2 Plavix Sales Forecast, 2012-2022
5.2.3 Generic Competition
5.2.4 Branded Competition
5.3 Lovenox
5.3.1 Lovenox Sales Forecast, 2012-2022
5.3.2 Competition for Lovenox
5.4 Pletal
5.4.1 Pletal Sales, 2010
5.4.2 Pletal Sales Forecast, 2012-2022
5.5 Fragmin
5.5.1 Fragmin Sales, 2010
5.5.2 Fragmin Sales Forecast, 2012-2022
5.6 Asasantin
5.6.1 Asasantin Sales, 2010
5.6.2 Asasantin Sales Forecast, 2012-2022
5.7 Arixtra
5.7.1 Arixtra Sales, 2010
5.7.2 Arixtra Sales Forecast, 2012-2022
5.8 Aspirin Cardio
5.8.1 Aspirin Cardio Sales, 2010
5.8.2 Aspirin Cardio Sales Forecast, 2012-2022
5.9 Opalmon
5.9.1 Opalmon Sales, 2010
5.9.2 Opalmon Sales Forecast, 2012-2022
5.10 Angiomax
5.10.1 Angiomax Sales, 2010
5.10.2 Angiomax Sales Forecast, 2012-2022
5.11 Activase
5.11.1 Activase Sales, 2010
5.11.2 Activase Sales Forecast, 2012-2022
5.12 Newly Launched Drugs, 2009-2011
5.12.1 Eli Lilly's Effient
5.12.1.1 Effient Sales Forecast, 2012-2022
5.12.1.2 Competition for Effient
5.12.2 Boehringer Ingelheim's Pradaxa
5.12.2.1 Pradaxa Sales Forecast, 2012-2022
5.12.2.2 Competition for Pradaxa
5.12.3 AstraZeneca's Brilinta
5.12.3.1 Brilinta Sales Forecast, 2012-2022
5.12.3.2 Competition for Brilinta
5.12.4 Johnson & Johnson/Bayer's Xarelto
5.12.4.1 Xarelto Sales Forecast, 2012-2022
5.12.4.2 Competition for Xarelto
5.13 Chapter Summary
6. Antithrombotic/Anticoagulant Drug R&D Pipeline
6.1 Platelet Aggregation Inhibitors R&D Pipeline, 2011
6.1.1 Portola/Novartis's Elinogrel
6.2 Heparins R&D Pipeline, 2011
6.2.1 Sanofi's Semuloparin
6.3 Fibrinolytics R&D Pipeline, 2011
6.3.1 Lundbeck/Berlex/Bayer's Desmoteplase
6.4 Direct Thrombin Inhibitors R&D Pipeline, 2011
6.4.1 Merck's Vorapaxar
6.4.2 Eisai's Atopaxar
6.5 Direct Factor Xa Inhibitors R&D Pipeline, 2011
6.5.1 BMS/Pfizer's Apixaban
6.5.2 Portola's Betrixaban
6.5.3 Daiichi Sankyo's Edoxaban
6.6 R&D Pipeline for Other Antithrombotic Drugs, 2011
6.6.1 Endotis/Merck's EP217609
7. SWOT and STEP Analyses
7.1 Principal Market Drivers
7.1.1 Rising Disease Prevalence
7.1.2 Risk Factors: Management Rather Than Cure
7.1.3 Opportunities for Continuous Growth
7.1.3.1 Standing Out from Competitors
7.1.3.2 Cost-Effective Replacement of Warfarin
7.1.3.3 Antidotes in Demand
7.1.3.4 Further Development of Existing Drugs
7.1.3.5 Exploring New Markets
7.1.4 Advances in Technology Will Bring Benefits to the Market
7.2 Principal Market Restraints
7.2.1 Highly Competitive Market
7.2.1.1 Generic Competition
7.2.1.2 Branded Competition
7.2.2 Cost-Reduction Pressure
7.2.3 Stringent Regulations
8. Research Interviews
8.1 Interview with Dr Charles E. Mahan (Director of Outcomes Research, New Mexico Heart Institute, Albuquerque, New Mexico)
8.1.1 Unmet Needs
8.1.2 Major Areas of Focus
8.1.3 New Drug Potential
8.1.4 Key Market Drivers
8.1.5 Opportunities for Revenue Growth
8.2 Interview with Dr Maurice Petitou (Head of Preclinical Research and Development, Endotis Pharma)
8.2.1 EP217609: The First Neutralizable Anticoagulant
8.2.2 Drug Targets Worth Exploring
8.2.3 New Drug Potential
8.2.4 Unmet Needs
8.3 Interview with Dr Jonathan L. Halperin (Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York)
8.3.1 Unmet Needs
8.3.2 New Findings
8.3.3 Warfarin Replacement
8.3.4 Areas Demanding Attention
8.3.5 Key Market Restraints
8.4 Interview with Dr Jeffrey I. Weitz (Professor of Medicine & Biochemistry, McMaster University, and Executive Director, Thrombosis & Atherosclerosis Research Institute, Ontario)
8.4.1 Unmet Needs
8.4.2 New Oral Anticoagulants
8.4.3 Future Areas of Focus
8.4.4 New Drug Potential
8.4.5 Market Drivers and Restraints
9. Conclusions
9.1 World Market Overview to 2022
9.2 Leading Drug Classes
9.3 Leading Products
9.4 Leading National Markets
9.5 The Future of the Antithrombotic/Anticoagulant Drug Market
9.5.1 Challenges
9.5.2 Opportunities
List of Tables
Table 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2016
Table 3.2 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2017-2022
Table 3.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Sales ($bn) and Market Shares (%), 2010
Table 3.4 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2010-2016
Table 3.5 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2017-2022
Table 3.6 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022
Table 3.7 Heparins: Market Forecast ($bn), 2010-2022
Table 3.8 Fibrinolytics: Market Forecast ($bn), 2010-2022
Table 3.9 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022
Table 3.10 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022
Table 3.11 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022
Table 4.1 Antithrombotic/Anticoagulant Drugs: Leading National Markets, 2010
Table 4.2 Leading National Markets: Forecasts ($bn), 2010-2022
Table 4.3 Antithrombotic/Anticoagulant Drug Market Shares (%) by Country, 2012 & 2022
Table 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022
Table 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010
Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2022
Table 5.3 Plavix Sales Forecast ($m), 2010-2022
Table 5.4 Lovenox Sales Forecast ($m), 2010-2022
Table 5.5 Pletal Sales Forecast ($m), 2010-2022
Table 5.6 Fragmin Sales Forecast ($m), 2010-2022
Table 5.7 Asasantin Sales Forecast ($m), 2010-2022
Table 5.8 Arixtra Sales Forecast ($m), 2010-2022
Table 5.9 Aspirin Cardio Sales Forecast ($m), 2010-2022
Table 5.10 Opalmon Sales Forecast ($m), 2010-2022
Table 5.11 Angiomax Sales Forecast ($m), 2010-2022
Table 5.12 Activase Sales Forecast ($m), 2010-2022
Table 5.13 Newly Launched Drugs, 2009-2011
Table 5.14 Effient Sales Forecast ($m), 2010-2022
Table 5.15 Pradaxa Sales Forecast ($m), 2011-2022
Table 5.16 Brilinta Sales Forecast ($m), 2011-2022
Table 5.17 Xarelto Sales Forecast ($m), 2011-2022
Table 6.1 Platelet Aggregation Inhibitors: R&D Pipeline, 2011
Table 6.2 Heparin Drugs: R&D Pipeline, 2011
Table 6.3 Fibrinolytics: R&D Pipeline, 2011
Table 6.4 Direct Thrombin Inhibitors: R&D Pipeline, 2011
Table 6.5 Direct Factor Xa Inhibitors: R&D Pipeline, 2011
Table 6.6 R&D Pipeline for Other Antithrombotic Agents, 2011
Table 7.1 SWOT Analysis, 2012-2022
Table 7.2 STEP Analysis, 2012-2022
Table 9.1 World Market Forecast ($bn), 2010-2022
List of Figures
Figure 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 3.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2010
Figure 3.3 Leading Therapeutic Class Forecast: Market Shares (%), 2012
Figure 3.4 Leading Therapeutic Class Forecast: Market Shares (%), 2022
Figure 3.5 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.6 Heparins: Market Forecast ($bn), 2010-2022
Figure 3.7 Fibrinolytics: Market Forecast ($bn), 2010-2022
Figure 3.8 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022
Figure 3.9 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.10 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.11 Antithrombotic/Anticoagulant Drugs: Therapeutic Class Market Shares (%), 2010, 2012 & 2022
Figure 4.1 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2010
Figure 4.2 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2012
Figure 4.3 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2022
Figure 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022
Figure 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010
Figure 5.2 Plavix Sales Forecast ($m), 2010-2022
Figure 5.3 Lovenox Sales Forecast ($m), 2010-2022
Figure 5.4 Pletal Sales Forecast ($m), 2010-2022
Figure 5.5 Fragmin Sales Forecast ($m), 2010-2022
Figure 5.6 Asasantin Sales Forecast ($m), 2010-2022
Figure 5.7 Arixtra Sales Forecast ($m), 2010-2022
Figure 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2022
Figure 5.9 Opalmon Sales Forecast ($m), 2010-2022
Figure 5.10 Angiomax Sales Forecast ($m), 2010-2022
Figure 5.11 Activase Sales Forecast ($m), 2010-2022
Figure 5.12 Effient Sales Forecast ($m), 2010-2022
Figure 5.13 Pradaxa Sales Forecast ($m), 2011-2022
Figure 5.14 Brilinta Sales Forecast ($m), 2011-2022
Figure 5.15 Xarelto Sales Forecast ($m), 2011-2022
Figure 6.1 New Antithrombotic Agents
Figure 9.1 Leading Drug Classes: Sales Forecasts ($bn), 2010-2022
Figure 9.2 Leading Drugs: Sales Projections ($m), 2010, 2012 & 2022
Figure 9.3 Leading National Markets: Sales Projections ($bn), 2010, 2012 & 2022